Last reviewed · How we verify
Sunitinib Malate Continuous Daily Dosing — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Sunitinib Malate Continuous Daily Dosing (Sunitinib Malate Continuous Daily Dosing) — Pfizer.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Sunitinib Malate Continuous Daily Dosing TARGET | Sunitinib Malate Continuous Daily Dosing | Pfizer | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Sunitinib Malate Continuous Daily Dosing CI watch — RSS
- Sunitinib Malate Continuous Daily Dosing CI watch — Atom
- Sunitinib Malate Continuous Daily Dosing CI watch — JSON
- Sunitinib Malate Continuous Daily Dosing alone — RSS
Cite this brief
Drug Landscape (2026). Sunitinib Malate Continuous Daily Dosing — Competitive Intelligence Brief. https://druglandscape.com/ci/sunitinib-malate-continuous-daily-dosing. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing